Clinical trials involving anti-CD19-CAR T-cells have shown better clinical responses in patients with ALL and chronic lymphocytic leukemia (CLL) when combined with cyclophosphamide conditioning (57, 87). Here, CD19 is linked to B-cell chronic lymphocytic leukemia.